The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Associations between longitudinal pretreatment BMI and neutrophil/lymphocyte ratio(NLR) and progression-free(PFS) and overall survival(OS) in advanced NSCLC patients treated with single agent anti-PD-1/anti-PDL1 monoclonal antibodies(mAbs).
 
Megan Randall
No Relationships to Disclose
 
Sanjib Basu
No Relationships to Disclose
 
Revathi Kollipara
No Relationships to Disclose
 
Marta Batus
No Relationships to Disclose
 
Philip D. Bonomi
Honoraria - AstraZeneca; Helsinn Therapeutics; Merck; pfizer; Spectrum Pharmaceuticals
Consulting or Advisory Role - AstraZeneca; Biodesix; Helsinn Therapeutics; Merck; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Biodesix (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Five Prime Therapeutics (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Hita Moudgalya
No Relationships to Disclose
 
Jeffrey Allen Borgia
Consulting or Advisory Role - Luminex
Research Funding - Biodesix; Pfizer
 
Mary J. Fidler
Honoraria - AstraZeneca; Genentech; Merck
Consulting or Advisory Role - Abbvie (I); AstraZeneca; G1 Therapeutics; Genentech (I); Rakuten Medical (Inst)
Speakers' Bureau - Genentech; Merck
Research Funding - AstraZeneca (Inst); Biodesix; CytomX Therapeutics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer/EMD Serono; Rakuten Medical (Inst)